PAUL A. MARKS, M.D.; BETTY S. ROOF, M.D.
This content is PDF only. Please click on the PDF icon to access.
"Myxedema heart" was first described as a clinical entity by Zondek1 in 1918. His description of the abnormal findings in patients with myxedema included enlargement of the heart, feeble cardiac pulsations, slow heart rate, normal blood pressure and reduced voltage in the electrocardiogram. These changes were found to be completely reversible upon treatment with thyroid hormone. Since this initial report there have been numerous observations2-8 confirming Zondek's findings.
The nature of the pathologic changes accounting for these cardiac disturbances has been a matter of some disagreement in the literature. The suggested changes include cardiac dilatation, fibrosis of the myocardium,
MARKS PA, ROOF BS. PERICARDIAL EFFUSION ASSOCIATED WITH MYXEDEMA*. Ann Intern Med. 1953;39:230–240. doi: https://doi.org/10.7326/0003-4819-39-2-230
Download citation file:
Published: Ann Intern Med. 1953;39(2):230-240.
Cardiology, Endocrine and Metabolism, Pericardial Disease, Thyroid Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use